Global Hyperlipidemia Drugs Market to Reach $38.1 Billion by 2030
The global market for Hyperlipidemia Drugs estimated at US$21.4 Billion in the year 2023, is expected to reach US$38.1 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. Statins Drug Class, one of the segments analyzed in the report, is expected to record a -6% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the PCSK9 Inhibitors Drug Class segment is estimated at 24.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $5.8 Billion, While China is Forecast to Grow at 18.1% CAGR
The Hyperlipidemia Drugs market in the U.S. is estimated at US$5.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.5 Billion by the year 2030 trailing a CAGR of 18.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 4.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook